Document is current
Any future updates will be listed below
-
Authors
Dieckmann, Linda https://orcid.org/0000-0002-1050-0098
Lahti-Pulkkinen, Marius
Kvist, Tuomas
Lahti, Jari
DeWitt, Peter E.
Cruceanu, Cristiana
Laivuori, Hannele
Sammallahti, Sara
Villa, Pia M.
Suomalainen-König, Sanna
Eriksson, Johan G.
Kajantie, Eero
Raikkönen, Katri
Binder, Elisabeth B.
Czamara, Darina
-
Funding
Funding for this research was provided by:
Academy of Finland (284859, 312670, 1324596)
Max Planck Institute of Psychiatry
- License Information
-
More Information
Article History
Received: 1 March 2021
Accepted: 14 April 2021
First Online: 29 April 2021
Declarations
:
: The ITU research protocol has been approved by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District (approval date: 06.01.2015, reference number: 269/13/03/00/09). Each ITU participant has signed a written informed consent form.The PREDO study protocol was approved by the Ethics Committee of Obstetrics and Gynaecology and Women, Children and Psychiatry of the Helsinki and Uusimaa Hospital District and by the participating hospitals. All participants provided written informed consent. Consent of participating children was provided by parent(s)/guardian(s). The study has been registered as ClinicalTrials.gov identifier ISRCTN14030412.
: Not applicable.
: EB is the coinventor of FKBP5: a novel target for antidepressant therapy, European Patent no. EP 1687443 B1, and receives a research grant from Böhringer Ingelheim for a collaboration on functional investigations of FKBP5. Otherwise, the authors declare that they have no competing interests.
